Overview: FMC7 Flow Cytometry TestIntroduction: The FMC7 Flow Cytometry Test detects FMC-7 markers to diagnose lymphoma, causing swollen lymph nodes or night sweats. Following 2023 ASH guidelines, it uses flow cytometry for high specificity, aiding in cancer screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in hematology for patients with suspected lymphoma.
Other Names: FMC7 Flow Assay, B-Cell Marker Test.
FDA Status: Laboratory-developed test (LDT), meeting hematology standards for diagnostic accuracy.
Historical Milestone: FMC7 testing began in the 1980s with lymphoma research. Flow cytometry emerged in the 1990s, and standardized panels improved accuracy by the 2000s.
Purpose: Diagnoses lymphoma, guides treatment, and monitors FMC-7 markers in patients with swollen lymph nodes or night sweats.
Test Parameters: 1. FMC-7
Pretest Condition: No fasting required. Collect whole blood or bone marrow at any time. Report symptoms like swollen lymph nodes or night sweats, and list medications.
Specimen: 2-5 mL whole blood (EDTA) or 2-5 mL bone marrow (EDTA). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document swollen lymph nodes, night sweats, or history of lymphoma. Include current medications, especially chemotherapeutics.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for cancer therapy.
Procedural Considerations: Uses flow cytometry to detect FMC-7 markers. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Poor sample quality or low cell yield can affect results. Non-malignant conditions may express FMC-7.
Clinical Significance: Positive FMC-7 expression suggests lymphoma, prompting treatment. Negative results may require additional marker testing.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation.
Additional Supporting Tests: Bone marrow biopsy, other flow cytometry markers (e.g., CD19, CD20), or PET scan to confirm lymphoma.
Test Limitations: Non-specific expression may occur in non-malignant conditions. Results require clinical correlation.
References: ASH Lymphoma Guidelines, 2023; Blood, Swerdlow SH, 2022.
